
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
A video summarizing key points of a presentation titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”
Here to discuss evidence-based practices in
Dr Citrome is a scheduled speaker at this year's US Psychiatric and Mental Health Congress in Orlando, Florida. His presentation is titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”






